Canada-based psychedelic drug manufacturer Optimi Health has partnered with PsiloThai, a patient advocacy group in Thailand. This collaboration follows Thailand's recent regulatory change permitting the use of psilocybin for medical treatment, research, and clinical trials. It marks Optimi's entry into the Asian medical market for observational studies involving psilocybin in patients with addiction and end-of-life distress.

The partnership aims to validate Optimi's GMP natural psilocybin extract capsules and explore psilocybin's therapeutic potential. It also allows Optimi to leverage PsiloThai's research capabilities and tap into Thailand's healthcare facilities and patient base.

Analyst QuickTake: Optimi previously expanded into the Israeli psychedelics market through a partnership with Tel Aviv University in March 2024. Additionally, its recent collaboration with Mind Medicine Australia to launch a resource platform for Australian psychiatrists underscores its commitment to supply safe psychedelic drugs globally.